Clinuvel (CUV)
Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial.
Joyce MoullakisSenior Reporter
Updated
Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial.
The trial aims to treat people with erythropoietic protoporphyria, a condition where patients are absolutely intolerant to visible and ultraviolet light.
Loading...
Joyce Moullakis wrote on banking and finance, specialising in Investment Banking, Private Equity, Financial Services. Connect with Joyce on Twitter. Email Joyce at jmoullakis@afr.com.au
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles